Sign in

    Vishal Balaji

    Research Analyst at Barclays

    Vishal Balaji is an analyst at Barclays who has participated in earnings calls covering companies such as Ligand Pharmaceuticals Inc., showcasing an emerging specialization in healthcare or pharmaceuticals equity research. His coverage includes detailed Q&A involvement with individual companies, although available performance metrics such as rankings, success rates, or average annualized returns remain undisclosed. Information about the start of his career, previous employers, and length of tenure at Barclays is currently limited, with no public documentation of notable achievements or sector-specific awards. Formal credentials such as securities licenses or FINRA registration have not been publicly verified.

    Vishal Balaji's questions to LIGAND PHARMACEUTICALS (LGND) leadership

    Vishal Balaji's questions to LIGAND PHARMACEUTICALS (LGND) leadership • Q4 2024

    Question

    Vishal Balaji, on for Balaji, asked for expectations on Ohtuvayre's growth, Ligand's view on the COPD maintenance therapy market, and the potential impact from biologic entrants like dupixent.

    Answer

    VP of Strategic Planning, Lauren Hay, expressed optimism for Ohtuvayre's strong launch trajectory, which she expects to be catalyzed by the new permanent J-code. She highlighted the large addressable market of 8.6 million patients and noted that Ohtuvayre targets a much larger population than biologics like dupixent, suggesting they serve different patient segments.

    Ask Fintool Equity Research AI